MARKET

ARTV

ARTV

ARTIVA BIOTHERAPEUTICS INC
NASDAQ
9.78
-0.90
-8.43%
After Hours: 10.10 +0.32 +3.27% 19:56 05/15 EDT
OPEN
10.60
PREV CLOSE
10.68
HIGH
10.70
LOW
9.60
VOLUME
524.52K
TURNOVER
--
52 WEEK HIGH
14.53
52 WEEK LOW
1.470
MARKET CAP
241.73M
P/E (TTM)
-2.7554
1D
5D
1M
3M
1Y
5Y
1D
Major Insider Move Signals Big Confidence in Artiva Biotherapeutics
TipRanks · 2d ago
RA Capital Management reports Artiva Biotherapeutics share buy worth $75 million
PUBT · 2d ago
Artiva Biotherapeutics Is Maintained at Buy by Needham
Dow Jones · 4d ago
Artiva Biotherapeutics Price Target Raised to $41.00/Share From $18.00 by Needham
Dow Jones · 4d ago
Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41
Benzinga · 4d ago
Needham Remains a Buy on Artiva Biotherapeutics, Inc. (ARTV)
TipRanks · 4d ago
ARTIVA BIOTHERAPEUTICS INC <ARTV.O>: NEEDHAM RAISES TARGET PRICE TO $41 FROM $18
Reuters · 4d ago
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
Reuters · 4d ago
More
About ARTV
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Webull offers Artiva Biotherapeutics Inc stock information, including NASDAQ: ARTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTV stock methods without spending real money on the virtual paper trading platform.